Seres Therapeutics (MCRB) News Today $0.77 +0.03 (+4.41%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period **Seres Therapeutics, Inc. Posts Updated Corporate Presentation - 8-K Filing Review****January 21 at 2:05 AM | americanbankingnews.comSeres Therapeutics announces receipt of expected $50M installment paymentJanuary 16, 2025 | markets.businessinsider.comSeres Receives $50 Mln Installment Payment Towards Sale Of VOWST Business To Nestle Health ScienceJanuary 16, 2025 | markets.businessinsider.comSeres Therapeutics receives $50 million from Nestlé Health ScienceJanuary 16, 2025 | msn.comSeres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST SaleJanuary 16, 2025 | globenewswire.comSeres Therapeutics Provides Corporate Updates and Financial ResultsJanuary 14, 2025 | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) Lowered to "Sell" Rating by StockNews.comJanuary 12, 2025 | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to "Sell"StockNews.com lowered shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday.January 11, 2025 | marketbeat.comSeres Therapeutics (MCRB) Receives a Buy from TD CowenJanuary 10, 2025 | markets.businessinsider.comSeres announces new translational biomarker results from SER-155 Phase 1b studyJanuary 10, 2025 | finance.yahoo.comSeres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate UpdatesJanuary 9, 2025 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.comStockNews.com upgraded shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.January 3, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Pass Above Fifty Day Moving Average - What's Next?Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Above 50-Day Moving Average - Time to Sell?January 2, 2025 | marketbeat.comThe past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitableDecember 26, 2024 | uk.finance.yahoo.comSeres Therapeutics (NASDAQ:MCRB) Shares Cross Below 200 Day Moving Average - Here's WhySeres Therapeutics (NASDAQ:MCRB) Stock Crosses Below Two Hundred Day Moving Average - What's Next?December 18, 2024 | marketbeat.comSeres Therapeutics to highlight plans for SER-155 at JPMorgan conferenceDecember 17, 2024 | finance.yahoo.comSeres Therapeutics to Participate in 2025 J.P. Morgan Healthcare ConferenceDecember 16, 2024 | globenewswire.comSeres’ SER-155 gains breakthrough status for BSIs reductionDecember 11, 2024 | finance.yahoo.comOptimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost ConfidenceDecember 11, 2024 | markets.businessinsider.comSeres Therapeutics to Participate in Piper Sandler Healthcare ConferenceNovember 22, 2024 | globenewswire.comSeres Therapeutics Reports Q3 2024 Results and Strategic ProgressNovember 15, 2024 | markets.businessinsider.comPromising Developments and Financial Stability Drive Buy Rating for Seres TherapeuticsNovember 15, 2024 | markets.businessinsider.comSeres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...November 15, 2024 | finance.yahoo.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.comSeres Therapeutics' (MCRB) Buy Rating Reaffirmed at Canaccord Genuity GroupCanaccord Genuity Group restated a "buy" rating and issued a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday.November 14, 2024 | marketbeat.comSeres reports Q3 EPS from continuing operations (33c), consensus (24c)November 14, 2024 | markets.businessinsider.comSeres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 13, 2024 | markets.businessinsider.comSeres Therapeutics Q3 2024 Earnings PreviewNovember 13, 2024 | msn.comWhat's Next: Seres Therapeutics's Earnings PreviewNovember 13, 2024 | benzinga.comSeres Therapeutics (NASDAQ:MCRB) Stock, Option ChainNovember 10, 2024 | benzinga.comSeres Therapeutics (MCRB) to Release Earnings on WednesdaySeres Therapeutics (NASDAQ:MCRB) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comSeres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024November 6, 2024 | globenewswire.comJP Morgan Downgrades Seres Therapeutics (MCRB)October 25, 2024 | msn.comSeres Therapeutics downgraded to Underweight from Neutral at JPMorganOctober 24, 2024 | markets.businessinsider.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) have earned a consensus rating of "Moderate Buy" from the three ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and two have given a buy ratingOctober 24, 2024 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Downgraded to Underweight at JPMorgan Chase & Co.JPMorgan Chase & Co. cut shares of Seres Therapeutics from a "neutral" rating to an "underweight" rating in a report on Thursday.October 24, 2024 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Crosses Below Fifty Day Moving Average - Here's What HappenedSeres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50 Day Moving Average - Time to Sell?October 15, 2024 | marketbeat.comSeres Therapeutics files for resale of common stock by holderOctober 2, 2024 | msn.comSeres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.ASeptember 30, 2024 | globenewswire.comSeres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With NestléSeptember 27, 2024 | finance.yahoo.comSeres Therapeutics (NASDAQ:MCRB) Stock, Insider Trading ActivitySeptember 27, 2024 | benzinga.comSeres Therapeutics Stockholders Approve Sale Of VOWST Business To Societe Des Produits NestleSeptember 27, 2024 | markets.businessinsider.comSeres Therapeutics, Inc.: Seres Therapeutics Stockholders Approve Sale of VOWST to Nestlé Health Science; Sale Expected to Close on September 30September 27, 2024 | finanznachrichten.deSeres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30September 26, 2024 | globenewswire.comSeres Therapeutics' Strategic Sale Of Vowst Warrants A Rating UpgradeSeptember 23, 2024 | seekingalpha.comBuy Rating Affirmed for Seres Therapeutics Amid Strong Clinical Outcomes for SER-155September 14, 2024 | markets.businessinsider.comSeres reports positive results in infection prevention studySeptember 13, 2024 | uk.investing.comOppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)September 13, 2024 | markets.businessinsider.comSeres Therapeutics (NASDAQ:MCRB) Rating Reiterated by Canaccord Genuity GroupCanaccord Genuity Group reaffirmed a "buy" rating and set a $10.00 target price on shares of Seres Therapeutics in a research report on Friday.September 13, 2024 | marketbeat.comSeres Therapeutics to Participate in Cantor 2024 Global Healthcare ConferenceSeptember 13, 2024 | globenewswire.com Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address MCRB Media Mentions By Week MCRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MCRB News Sentiment▼0.190.48▲Average Medical News Sentiment MCRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MCRB Articles This Week▼52▲MCRB Articles Average Week Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ERAS News Today VERV News Today STOK News Today RNAC News Today MGTX News Today ALT News Today PROK News Today ANAB News Today XERS News Today PHAT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MCRB) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MCRB Stock Alerts